menu
    • menu

    Company profile for Exavir Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. Our ultra-long acting antiretroviral portfolio is a multi-class arsenal for HIV treatment and prevention regimens. Our agents are de-risked by existing antiretrovirals that are proven to work at target drug exposure l...
    Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. Our ultra-long acting antiretroviral portfolio is a multi-class arsenal for HIV treatment and prevention regimens. Our agents are de-risked by existing antiretrovirals that are proven to work at target drug exposure levels.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Exavir TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Francisco, CA, United States
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://exavirtherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/exavir-therapeutics/about/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ExavirTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aion Shows AM-710 Data at ObesityWeek on Ultra-Long-Acting GLP-1
    Aion Shows AM-710 Data at ObesityWeek on Ultra-Long-Acting GLP-1

    04 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251104746008/en/Aion-Medicines-Presents-Data-at-ObesityWeek-Demonstrating-Ultra-long-acting-Pharmacokinetics-and-Pharmacodynamic-Effects-of-AM-710-a-Potential-Best-in-class-GLP-1-Receptor-Agonist-and-the-Longest-Acting-Incretin-Identified-to-Date

    BUSINESSWIRE
    04 Nov 2025
    Share Share
    Exavir Settles, Licenses Ultra-Long HIV Compounds To ViiV
    Exavir Settles, Licenses Ultra-Long HIV Compounds To ViiV

    22 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240522307113/en

    BUSINESSWIRE
    22 May 2024
    Share Share
    Exavir Receives $3M Award from NIH / NIAID to Advance Inhibitor XVIR-110
    Exavir Receives $3M Award from NIH / NIAID to Advance Inhibitor XVIR-110

    22 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230822179307/en

    BUSINESSWIRE
    22 Aug 2023
    Share Share
    GSK’s ViiV Sues Exavir Over Licensing Pact on HIV-Drug Compounds
    GSK’s ViiV Sues Exavir Over Licensing Pact on HIV-Drug Compounds

    01 Nov 2022

    // BLOOMBERGLAW

    https://news.bloomberglaw.com/health-law-and-business/gsks-viiv-sues-exavir-over-licensing-pact-on-hiv-drug-compounds?context=search&index=12

    BLOOMBERGLAW
    01 Nov 2022
    Share Share
    Exavir to publish PC data for ultra-long-acting dolutegravir prodrug XVIR-120
    Exavir to publish PC data for ultra-long-acting dolutegravir prodrug XVIR-120

    09 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/09/2459524/0/en/Exavir-Therapeutics-announces-publication-of-preclinical-data-for-ultra-long-acting-dolutegravir-prodrug-XVIR-120.html

    GLOBENEWSWIRE
    09 Jun 2022
    Share Share
    Exavir Therapeutics Completes $4M Seed Financing from Key Investors
    Exavir Therapeutics Completes $4M Seed Financing from Key Investors

    23 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/23/2448266/0/en/Exavir-Therapeutics-Completes-4M-Seed-Financing-from-Key-Investors.html

    GLOBENEWSWIRE
    23 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search